Leerink Partnrs Decreases Earnings Estimates for Biohaven

Biohaven Ltd. (NYSE:BHVN) – Research analysts at Leerink Partnrs cut their FY2025 earnings per share estimates for shares of Biohaven in a research note issued on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now expects that the company will post earnings per share of ($6.90) for the year, down from their prior estimate of ($6.05). The consensus estimate for Biohaven’s current full-year earnings is ($8.85) per share. Leerink Partnrs also issued estimates for Biohaven’s FY2027 earnings at ($3.50) EPS and FY2028 earnings at ($1.65) EPS.

Several other research firms have also recently commented on BHVN. TD Cowen upped their target price on shares of Biohaven from $55.00 to $75.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Biohaven in a research report on Tuesday, December 17th. HC Wainwright reiterated a “buy” rating and issued a $59.00 target price on shares of Biohaven in a research note on Tuesday, December 17th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $61.00 price target (up from $58.00) on shares of Biohaven in a research note on Wednesday, December 4th. Thirteen analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $63.00.

Biohaven Stock Down 1.8 %

Shares of BHVN stock opened at $38.30 on Friday. Biohaven has a 12 month low of $26.80 and a 12 month high of $62.21. The firm has a market cap of $3.87 billion, a PE ratio of -4.10 and a beta of 1.29. The stock has a 50 day moving average of $39.65 and a 200-day moving average of $42.49.

Biohaven (NYSE:BHVN) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($1.70) earnings per share for the quarter, missing the consensus estimate of ($1.67) by ($0.03).

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of BHVN. Hsbc Holdings PLC increased its holdings in Biohaven by 6.1% during the 2nd quarter. Hsbc Holdings PLC now owns 8,291 shares of the company’s stock valued at $286,000 after purchasing an additional 480 shares in the last quarter. Squarepoint Ops LLC bought a new stake in shares of Biohaven during the second quarter worth $592,000. AQR Capital Management LLC increased its stake in shares of Biohaven by 234.3% in the second quarter. AQR Capital Management LLC now owns 54,361 shares of the company’s stock valued at $1,887,000 after buying an additional 38,101 shares in the last quarter. The Manufacturers Life Insurance Company raised its holdings in shares of Biohaven by 12.3% in the second quarter. The Manufacturers Life Insurance Company now owns 183,772 shares of the company’s stock valued at $6,379,000 after buying an additional 20,154 shares during the last quarter. Finally, Algert Global LLC lifted its position in Biohaven by 5.9% during the 2nd quarter. Algert Global LLC now owns 7,402 shares of the company’s stock worth $257,000 after buying an additional 412 shares in the last quarter. Institutional investors own 88.78% of the company’s stock.

Insiders Place Their Bets

In other news, Director John W. Childs acquired 29,000 shares of the firm’s stock in a transaction on Monday, December 30th. The shares were purchased at an average cost of $35.94 per share, with a total value of $1,042,260.00. Following the completion of the purchase, the director now owns 2,368,741 shares of the company’s stock, valued at $85,132,551.54. This represents a 1.24 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 16.00% of the company’s stock.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.